BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 7,604 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $26.11 on Friday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -24.63 and a beta of 1.91. The firm has a 50-day moving average of $24.78 and a two-hundred day moving average of $23.66. BioLife Solutions, Inc. has a 1 year low of $14.50 and a 1 year high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Analyst Ratings Changes

Several research firms have commented on BLFS. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Thursday. KeyCorp increased their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of BioLife Solutions in the 3rd quarter worth $28,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 42,265 shares during the period. 1620 Investment Advisors Inc. purchased a new stake in BioLife Solutions in the second quarter worth about $35,000. Quest Partners LLC purchased a new stake in BioLife Solutions in the third quarter worth about $57,000. Finally, GAMMA Investing LLC grew its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.